Screening for Pancreatic Cancer in High-Risk Individuals

Video

For High-Definition, Click

Effective screening for pancreatic cancer remains heavily a research question. At this time, no major professional group recommends routine population-based screening nor has any screening test been shown to lower the risk of death from the disease.

One challenge facing screening for pancreatic cancer is a lack of a proven selection process to determine which patients constitute the appropriate high-risk group to target. As a result, it is unclear exactly who needs to be to be screened, at what age to start, or at what intervals, Philip Philip, MD, PhD, explains.

What to do with the findings is also often uncertain, recognizing the potential for an invasive intervention that may not be necessary in an otherwise healthy patient following a false positive, Philip notes. However, major academic centers have screening programs and are collaborating to answer questions regarding the best approach.

For these reasons, population-based screening for pancreatic cancer is not something to expect in the near future. However, there are several small groups of people known to be at higher risk, such as those with positive family history, Lynch Syndrome, or BRCA mutations, explains Eileen O’Reilly, MD. Noninvasive imaging tools can be used for early detection in these patients. Some screening programs have incorporated using alternating endoscopic ultrasound and MRI in the very high-risk population, since exposing these patients to radiation with routine CT scans is less desirable.

Related Videos
Video 6 - "Patient Case 2: A 62-Year-Old Woman with Metastatic Rectal Cancer"
Video 5 - "Adverse Events Associated With TAS-102 Plus Bevacizumab in CRC"
Michael J. Overman, MD
Ilyas Sahin, assistant professor, Medicine, Department of Medicine, Division of Hematology & Oncology, University of Florida College of Medicine
Michael J. Overman, MD
Manish A. Shah, MD, director, Gastrointestinal Oncology Program, Weill Cornell Medicine; chief, Solid Tumor Service, co-director, Center for Advanced Digestive Disease, NewYork Presbyterian
Katrina S. Pedersen, MD, MS
Efrat Dotan, MD
In this fifth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss next steps for research, including vaccination strategies, personalized cellular therapies, and more.
In this fourth episode of OncChats: Leveraging Immunotherapy in GI Malignancies, experts discuss research efforts being made with organoids to address existing questions with immunotherapy and the exploration of multimodality approaches to improve outcomes.